DRUG ELUTING BALLOON MARKET ANALYSIS

Lack of proper reimbursement policies across different geographies can hamper the growth of global drug eluting balloon market. In the case of drug eluting balloons, the reimbursement scenarios vary significantly across countries and regions. In many developing nations, there are no established reimbursement codes or payment guidelines for procedures that utilize drug eluting balloons. Healthcare facilities have to bear the costs of procuring these high-priced medical devices from their own budgets, without any assurance of being compensated for their use. This discourages hospitals and clinics from stocking and using drug eluting balloons, especially for treating conditions like peripheral artery disease, when plain old balloon angioplasty, a much cheaper alternative, is available. Even in developed markets, the reimbursement policies favor traditional uncoated balloons over drug coated versions in some cases.

Market Opportunity – Increasing Inorganic Growth Strategies by Key Market Players

Increasing adoption of inorganic growth strategies, such as acquisition, by key market players is expected to offer lucrative growth opportunities over the forecast period. For instance, in October 2022, Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, announced the acquisition of Med Alliance SA, a medical technology company. The acquisition enabled Cordis will immediately begin co-promotion of MedAlliance’s SELUTION SLR drug-eluting balloon in markets where it is commercially available.